Medicinal Plants as Emerging Frontiers in the Battle against Multi Drug-Resistant Micrograms and Opportunistic Pathogens

Introduction

The rapid emergence and global spread of multidrug-resistant (MDR) microorganisms have become a critical concern for public health systems worldwide. The overuse, misuse, and indiscriminate application of conventional antibiotics in clinical and agricultural sectors have accelerated the evolution of resistant strains, rendering many first-line and even last-resort drugs ineffective [1]. As a result, common infections caused by bacteria, fungi, and other opportunistic pathogens have become increasingly difficult to treat, leading to higher mortality rates, prolonged hospital stays, and soaring healthcare costs. The World Health Organization (WHO) has repeatedly highlighted antimicrobial resistance (AMR) as one of the top ten global public health threats facing humanity, emphasizing the urgent need for novel and effective antimicrobial agents, the growing AMR crisis, researchers and healthcare professionals are exploring alternative approaches that go beyond conventional antibiotics. Among these, natural products derived from medicinal plants have attracted significant attention due to their diverse chemical structures and broad-spectrum biological activities. Unlike synthetic drugs, phytochemicals often exhibit multifactorial mechanisms of action, targeting various microbial processes simultaneously, which reduces the risk of resistance development [2], the ecological role of plant secondary metabolites, often evolved as defense mechanisms against pathogens, offers an evolutionary advantage in their antimicrobial potential [3]. This has led to a resurgence of interest in ethnopharmacology and traditional medicine as valuable sources for antimicrobial discovery.

Medicinal plants harbor a wide array of bioactive compounds, including alkaloids, flavonoids, tannins, terpenoids, saponins, and phenolic acids, each contributing to antimicrobial efficacy through different mechanisms. These compounds may disrupt microbial cell wall integrity, inhibit protein or nucleic acid synthesis, impede metabolic pathways, or interfere with essential enzymes, certain phytochemicals possess the ability to inhibit biofilm formation and quorum sensing, both of which are critical for microbial virulence and resistance, these unique microbial processes, plant-derived compounds offer a strategic advantage in the fight against MDR pathogens, particularly in tackling opportunistic infections prevalent in immunocompromised individuals [4].

Opportunistic pathogens such as Pseudomonas aeruginosa, Candida albicans, and Acinetobacter baumannii have emerged as significant threats in healthcare settings, primarily affecting patients with weakened immune systems or underlying conditions. These pathogens often display resistance to multiple antibiotics and can persist in hospital environments due to their robust biofilm-forming capabilities. Medicinal plants, through their diverse phytochemical arsenal, have shown promising results against these pathogens in various in vitro and in vivo studies. The ability of plant extracts to modulate host immune responses further enhances their therapeutic potential, suggesting a dual role in both antimicrobial and immunomodulatory applications [5]. Another important aspect is the synergistic interaction between plant-derived compounds and existing antibiotics. Studies have demonstrated that combining phytochemicals with conventional antimicrobials can enhance their efficacy, lower the required dosage, and even restore the activity of drugs rendered ineffective by resistance. This synergy not only improves treatment outcomes but also reduces the likelihood of adverse side effects associated with high antibiotic doses. The concept of combination therapy opens new avenues for integrating natural products into mainstream medical practice, fostering a multidisciplinary approach to managing MDR infections. , medicinal plants represent a promising frontier in the battle against multidrug-resistant microorganisms and opportunistic pathogens. Their rich phytochemical diversity, multifaceted mechanisms of action, potential for synergy with conventional drugs, and historical significance in traditional medicine systems position them as invaluable assets in contemporary drug discovery [6]. As research continues to unveil the complex interactions between plant bio-actives and microbial pathogens, the development of plant-based therapeutics may offer sustainable and effective solutions to one of the most pressing challenges in modern medicine.

The alarming rise of multidrug-resistant (MDR) microorganisms presents a major challenge to global health, with increasing numbers of bacterial, fungal, and viral strains showing resistance to multiple classes of antibiotics. MDR pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa, have been implicated in severe infections with limited or no effective treatment options. The frequent misuse and over-prescription of antibiotics, combined with poor infection control practices, have accelerated resistance mechanisms such as mutation, horizontal gene transfer, and biofilm formation. Consequently, MDR infections have contributed to increased morbidity, prolonged hospital stays, higher treatment costs, and elevated mortality rates worldwide [7]. Traditional antibiotics typically target specific bacterial pathways or structures, making them vulnerable to resistance mechanisms like efflux pump activation, enzymatic degradation, or target site modification. As pathogens continue to evolve rapidly, the existing antibiotic pipeline struggles to keep pace, creating an urgent need for alternative antimicrobial strategies, opportunistic infections in immunocompromised patients—such as those with cancer, HIV, or post-transplant—are especially problematic due to limited treatment choices against resistant strains. This scenario underscores the critical necessity of identifying new antimicrobial sources, among which medicinal plants stand out as a promising frontier with immense potential to combat MDR pathogens.

Bioactive Phytochemicals from Medicinal Plants: Nature’s Arsenal

Medicinal plants are a rich source of bioactive phytochemicals, which have evolved as part of the plants’ defense mechanisms against pathogens and herbivores. These compounds include alkaloids, flavonoids, tannins, terpenoids, phenolic acids, and saponins, each exhibiting distinct antimicrobial properties. For example, alkaloids may disrupt nucleic acid synthesis or interfere with protein synthesis, while flavonoids can inhibit microbial enzymes and compromise cell membrane integrity. These compounds often work in complex synergy within the plant extract, offering broad-spectrum antimicrobial activity that targets multiple pathways simultaneously—a feature that reduces the risk of resistance development in pathogens, the structural diversity and chemical complexity of plant-derived compounds allow them to act on various microbial targets, including bacterial cell walls, membrane proteins, intracellular enzymes, and genetic material. Unlike single-target antibiotics, these multifactorial interactions hinder the pathogen’s ability to develop effective resistance mechanisms [8]. The growing body of research supporting the antimicrobial potential of phytochemicals highlights their relevance in both standalone therapies and adjunct treatments. As advances in phytochemistry and pharmacognosy continue, the exploration of these natural compounds opens new possibilities for developing novel drugs and combination therapies designed to address the MDR crisis.

Mechanisms of Action: How Medicinal Plants Counteract MDR Pathogens

One of the most significant advantages of medicinal plants in combating MDR pathogens is their diverse mechanisms of action. Phytochemicals from medicinal plants can disrupt microbial cell walls and membranes, leading to leakage of cellular contents and eventual cell death. This action is particularly effective against bacteria and fungi that rely on robust cell wall structures for survival. Furthermore, certain plant compounds can bind to microbial enzymes, inhibit essential metabolic pathways, or interfere with the synthesis of DNA and proteins, thereby preventing the microorganism from replicating and spreading. This multifaceted approach makes it difficult for pathogens to adapt or develop resistance compared to conventional antibiotics with single molecular targets [9]. Another crucial mechanism involves the inhibition of biofilm formation and quorum sensing—processes central to microbial virulence and resistance. Biofilms protect bacteria from hostile environments, including antibiotic treatment, by creating a dense extracellular matrix that impedes drug penetration. Phytochemicals like curcumin, flavonoids, and alkaloids have been shown to prevent biofilm formation and disrupt pre-formed biofilms, making the microbes more susceptible to host defenses and conventional antibiotics. Additionally, by interfering with quorum sensing, plant compounds can inhibit microbial communication, thereby reducing toxin production, virulence factor expression, and resistance gene dissemination among pathogens. These combined actions underline the therapeutic potential of medicinal plants in addressing persistent infections caused by MDR pathogens.

Synergistic Effects with Conventional Antimicrobials: A Promising Strategy

The concept of synergy between medicinal plant extracts and conventional antibiotics is gaining considerable attention in antimicrobial research. Synergistic combinations can enhance the efficacy of antibiotics by increasing their potency, expanding their spectrum of activity, or overcoming resistance mechanisms such as efflux pump activation and enzymatic degradation. For example, when plant extracts inhibit bacterial efflux pumps, they prevent the expulsion of antibiotics from microbial cells, thus increasing intracellular drug concentrations and restoring antibiotic activity [10]. This approach is particularly useful against pathogens that have developed resistance through active efflux systems or beta-lactamase production, synergy allows for lower doses of both antibiotics and plant extracts, which can reduce the risk of adverse side effects and toxicity associated with high-dose antibiotic therapies. Several studies have reported successful combinations of phytochemicals like allicin from garlic, curcumin from turmeric, and catechins from green tea with commonly used antibiotics, resulting in improved antimicrobial outcomes against MDR strains. These findings not only support the use of plant-based compounds as adjuvants but also encourage further clinical research into standardized herbal-antibiotic formulations. By leveraging the complementary mechanisms of action, such combination therapies offer a promising strategy for enhancing treatment efficacy and mitigating the threat of antimicrobial resistance.

Targeting Opportunistic Pathogens: The Role of Medicinal Plants in Clinical Settings

Opportunistic pathogens, such as Pseudomonas aeruginosa, Candida albicans, and Acinetobacter baumannii, pose a significant risk in healthcare settings, particularly among immunocompromised patients and those undergoing invasive procedures. These pathogens often display intrinsic or acquired resistance to multiple antibiotics, making infections difficult to manage and contributing to high morbidity and mortality rates. Medicinal plants, with their broad-spectrum antimicrobial properties and immune-modulating effects, offer a valuable therapeutic option against these opportunistic infections [11]. Research has demonstrated that certain plant extracts can directly inhibit the growth of these pathogens or disrupt their ability to adhere to host tissues and form protective biofilms.

Beyond their direct antimicrobial action, medicinal plants may also bolster the host immune response, providing a dual mechanism of defense against opportunistic pathogens. Compounds like flavonoids and terpenoids have been noted for their anti-inflammatory and immunomodulatory properties, which can enhance innate immunity and reduce the severity of infections. This holistic approach—combining antimicrobial action with immune support—holds particular promise in clinical settings where patients are vulnerable to opportunistic infections due to compromised immunity [12]. As such, integrating medicinal plant-based therapies into infection control protocols may improve patient outcomes and reduce the reliance on conventional antibiotics, thereby contributing to a broader strategy for managing multidrug-resistant and opportunistic infections.

Inhibition of Biofilm Formation by Medicinal Plant Compounds

Biofilms are structured communities of microorganisms enclosed within a self-produced extracellular matrix, which provides protection against antibiotics and host immune responses. These biofilms are particularly problematic in chronic infections, medical device contamination, and hospital-acquired infections. Many opportunistic pathogens, such as Pseudomonas aeruginosa and Candida albicans, rely on biofilm formation to enhance their resistance and persistence. Medicinal plant extracts rich in bioactive compounds like flavonoids, phenolics, and terpenoids have demonstrated the ability to inhibit biofilm formation by interfering with microbial adhesion, extracellular matrix production, and quorum sensing pathways, thereby weakening the biofilm structure and reducing microbial survival, some phytochemicals are capable of disrupting already established biofilms, which is a significant advantage over many conventional antibiotics that fail to penetrate the biofilm matrix [13]. The anti-biofilm activity of medicinal plants not only helps in eradicating persistent infections but also enhances the effectiveness of co-administered antibiotics. This makes medicinal plants a valuable adjunct in the treatment of biofilm-associated infections. Continued research on plant-derived anti-biofilm agents could pave the way for new therapies targeting this critical aspect of microbial resistance and pathogenesis.

Quorum Sensing Inhibition: Disrupting Microbial Communication

Quorum sensing (QS) is a sophisticated cell-to-cell communication system used by bacteria to coordinate gene expression based on population density. This system regulates various physiological activities, including biofilm formation, virulence factor production, and resistance gene expression. Medicinal plant compounds have been found to interfere with quorum sensing pathways, effectively silencing microbial communication and reducing pathogenicity without exerting direct bactericidal pressure, which helps minimize resistance development. Phytochemicals such as coumarins, flavonoids, and alkaloids have shown significant quorum sensing inhibitory activities against both Gram-positive and Gram-negative bacteria. By targeting quorum sensing, medicinal plant extracts can prevent the expression of harmful genes and disrupt microbial coordination required for infection establishment [14]. This mode of action offers a strategic advantage in antimicrobial therapy, especially against MDR organisms that rely on QS-regulated mechanisms for survival and virulence, combining quorum sensing inhibitors with traditional antibiotics may enhance therapeutic outcomes, making this an attractive field for further pharmacological exploration.

Modulation of Efflux Pumps: Enhancing Antibiotic Potency

Efflux pumps are transport proteins in bacterial and fungal cells that actively expel antibiotics and other toxic substances, contributing significantly to multidrug resistance. The overexpression of these efflux pumps reduces the intracellular concentration of antibiotics, rendering treatments ineffective. Medicinal plants contain natural efflux pump inhibitors (EPIs) such as alkaloids, flavonoids, and terpenoids, which can block or reduce the activity of these pumps [15]. By inhibiting efflux pumps, phytochemicals restore the susceptibility of MDR pathogens to conventional antibiotics, making them more effective at lower doses. The use of plant-derived EPIs in combination with existing antibiotics represents a promising strategy for overcoming efflux-mediated resistance. Studies have shown that compounds like reserpine (from Rauwolfia serpentina) and piperine (from Piper nigrum) can inhibit major efflux systems in bacteria. This synergistic approach not only revitalizes the potency of older antibiotics but also extends their clinical utility against resistant infections, emphasizing the need for continued research into plant-based efflux pump modulators.

Plant-Derived Antifungal Agents: Addressing Fungal Resistance

Fungal infections, particularly those caused by Candida species and Aspergillus species, have emerged as a serious health threat, especially in immunocompromised patients. Resistance to commonly used antifungal drugs like azoles and echinocandins is on the rise, complicating treatment protocols. Medicinal plants offer a promising source of antifungal agents with diverse mechanisms of action, including disruption of fungal cell wall synthesis, membrane integrity, and enzyme inhibition [16]. Compounds such as eugenol, thymol, and berberine have shown potent antifungal activities in various studies. Additionally, plant-derived antifungal agents often exhibit immunomodulatory properties, enhancing the host’s ability to combat fungal infections naturally. The multifaceted mechanisms of action exhibited by these phytochemicals reduce the likelihood of resistance development compared to single-target synthetic antifungals. As research progresses, medicinal plants may provide a valuable arsenal in the fight against fungal infections, particularly those resistant to current antifungal therapies.

Antiviral Potential of Medicinal Plant Extracts

Viruses, including emerging pathogens like coronaviruses, pose a unique challenge due to their rapid mutation rates and limited treatment options. Antiviral resistance, although less common than bacterial resistance, is a growing concern, particularly in chronic viral infections like HIV and hepatitis. Medicinal plants have demonstrated antiviral activity through various mechanisms, such as inhibition of viral entry into host cells, disruption of viral replication, and interference with viral protein synthesis. Phytochemicals like flavonoids, alkaloids, and polyphenols have shown promise against a broad range of viruses in preclinical studies. Moreover, the immunomodulatory effects of certain plant extracts can enhance antiviral immunity, aiding the body in clearing infections more effectively [12]. The potential of plant-based antivirals in preventing or mitigating viral infections warrants further investigation, especially in the context of pandemics and drug-resistant viral strains. As natural products continue to be explored, they may offer alternative or complementary therapies in antiviral treatment regimens.

Immunomodulatory Effects of Medicinal Plants in Infection Control

Beyond their direct antimicrobial activities, many medicinal plants exert immunomodulatory effects that help strengthen the body’s natural defenses against infections. These effects include stimulating immune cell activity, enhancing the production of cytokines and antibodies, and modulating inflammatory responses. Immunomodulatory phytochemicals, such as polysaccharides, flavonoids, and saponins, can improve host resistance to infections and assist in quicker recovery, enhancing the host immune response is critical, especially for opportunistic infections in immunocompromised individuals. By boosting immunity, medicinal plants can help the body mount a more effective response to pathogens while potentially reducing the need for high-dose antibiotic treatments [9]. This dual role in antimicrobial action and immune support makes medicinal plants a valuable component in integrated infection management strategies.

Ethnopharmacological Knowledge: Bridging Traditional Medicine with Modern Research

Ethnopharmacology, the study of traditional medicinal practices and the bioactive compounds in indigenous plants, has been instrumental in identifying potential antimicrobial agents. Many medicinal plants used in traditional healing systems like Ayurveda, Traditional Chinese Medicine (TCM), and Unani have been scientifically validated for their antimicrobial properties. This traditional knowledge provides a valuable foundation for modern drug discovery, allowing researchers to focus on plants with known therapeutic benefits. The integration of ethnopharmacological knowledge with contemporary scientific methods can accelerate the discovery of novel antimicrobials and facilitate the development of standardized herbal formulations [4]. Moreover, respecting and preserving indigenous knowledge ensures ethical research practices and promotes sustainable use of medicinal plant resources. As interest in natural remedies grows, bridging traditional wisdom with modern pharmacology will be essential for developing effective therapies against MDR pathogens.

Phytochemical Synergy: The Power of Combined Plant Compounds

Phytochemical synergy refers to the phenomenon where multiple bioactive compounds within a plant extract work together to enhance therapeutic effects. Unlike synthetic drugs that often contain a single active ingredient, medicinal plant extracts comprise a complex mixture of compounds that can act synergistically to increase antimicrobial efficacy, reduce toxicity, and target multiple microbial pathways. This synergistic interaction not only boosts antimicrobial activity but also helps in reducing the risk of resistance development [12]. Research has shown that combinations of flavonoids, alkaloids, and terpenoids within a single extract can produce stronger antimicrobial effects than isolated compounds. Understanding and harnessing this synergy is vital for optimizing the therapeutic potential of plant-based remedies. The study of phytochemical interactions could lead to the formulation of multi-component herbal therapies with enhanced efficacy against multidrug-resistant pathogens.

Safety and Toxicity Considerations in Medicinal Plant Use

While medicinal plants offer numerous therapeutic benefits, their safety and toxicity profiles must be carefully evaluated. The assumption that natural products are inherently safe is misleading, as certain plant-derived compounds can exhibit cytotoxicity, allergenicity, or adverse interactions with conventional drugs. Therefore, thorough pharmacological and toxicological assessments are crucial before clinical application [11]. Standardizing plant extracts, determining optimal dosages, and conducting rigorous clinical trials are necessary steps to ensure safety and efficacy. Moreover, potential drug-herb interactions must be assessed, especially when medicinal plants are used alongside conventional antibiotics or antifungal agents. Addressing these safety considerations is key to gaining regulatory approval and acceptance in mainstream healthcare systems.

Future Prospects: Integrating Medicinal Plants into Antimicrobial Therapy

The future of antimicrobial therapy lies in a multidisciplinary approach that integrates medicinal plant research with modern pharmacology, biotechnology, and clinical medicine. Advances in phytochemical analysis, bioinformatics, and high-throughput screening are accelerating the identification of potent plant-derived antimicrobials. Additionally, the development of novel drug delivery systems, such as nano-formulations, could enhance the bioavailability and therapeutic efficacy of plant-based compounds. The ongoing global effort to combat antimicrobial resistance underscores the urgent need for innovative therapies, in which medicinal plants will likely play a pivotal role. By fostering continued research, ensuring safety, and promoting sustainable use, medicinal plants can be effectively integrated into modern antimicrobial strategies to address the growing challenge of multidrug-resistant and opportunistic infections.

Conclusion

The escalating threat of multidrug-resistant (MDR) microorganisms and opportunistic pathogens has amplified the urgency for alternative therapeutic strategies beyond conventional antibiotics. Medicinal plants, with their rich reservoir of diverse bioactive phytochemicals, offer a promising frontier in this global health battle. Their ability to act on multiple microbial targets, disrupt resistance mechanisms like biofilm formation, quorum sensing, and efflux pumps, makes them highly valuable in addressing persistent and hard-to-treat infections. Moreover, plant-derived compounds’ potential to work synergistically with existing antibiotics opens new avenues for combination therapies that can enhance antimicrobial efficacy and reduce the risks associated with drug resistance. The multifaceted antimicrobial activities of medicinal plants provide a scientific basis for their integration into modern pharmacotherapy as adjuncts or standalone treatments. In addition to their direct antimicrobial properties, medicinal plants possess significant immunomodulatory and anti-inflammatory effects that strengthen host defenses against infections, particularly in immunocompromised individuals vulnerable to opportunistic pathogens. This dual mechanism of action—targeting both pathogens and supporting host immunity—underscores their unique advantage over many conventional drugs, the insights gained from ethnopharmacology and traditional medicine systems have guided modern research toward the discovery of new plant-based antimicrobial agents, it is crucial to recognize the importance of thorough pharmacological evaluation, toxicity testing, and clinical trials to ensure the safe and effective application of these natural resources in healthcare settings, the integration of medicinal plant research with advanced scientific tools such as bioinformatics, nanotechnology, and drug delivery systems holds great promise in enhancing the therapeutic potential of plant-based antimicrobials. Sustainable sourcing, ethical research practices, and standardized extraction methods will be critical for the responsible development of plant-derived drugs.

References

• Parveen, M., & Some, S. (2021). Antimicrobial activity of medicinal plants: a weapon to combat multi-drug resistant pathogens. International Journal of Plant and Environment, 7(02), 133-141.
• Chawla, M., Verma, J., Gupta, R., & Das, B. (2022). Antibiotic potentiators against multidrug-resistant bacteria: discovery, development, and clinical relevance. Frontiers in microbiology, 13, 887251.
• Khan, S. N., & Khan, A. U. (2016). Breaking the spell: combating multidrug resistant ‘superbugs’. Frontiers in microbiology, 7, 174.
• Brooke, J. S. (2014). New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert review of anti-infective therapy, 12(1), 1-4.
• Brooke, J. S. (2014). New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert review of anti-infective therapy, 12(1), 1-4.
• Cheepurupalli, L., Raman, T., Rathore, S. S., & Ramakrishnan, J. (2017). Bioactive molecule from Streptomyces sp. mitigates MDR Klebsiella pneumoniae in Zebrafish infection model. Frontiers in Microbiology, 8, 614.
• Panda, S. K., Buroni, S., Swain, S. S., Bonacorsi, A., da Fonseca Amorim, E. A., Kulshrestha, M., & Tiwari, V. (2022). Recent advances to combat ESKAPE pathogens with special reference to essential oils. Frontiers in Microbiology, 13, 1029098.
• Wylie, M. R., & Merrell, D. S. (2022). The antimicrobial potential of the neem tree Azadirachta indica. Frontiers in pharmacology, 13, 891535.
• Molina‐Santiago, C., Daddaoua, A., Gómez‐Lozano, M., Udaondo, Z., Molin, S., & Ramos, J. L. (2015). Differential transcriptional response to antibiotics by P seudomonas putida DOT‐T1E. Environmental microbiology, 17(9), 3251-3262.
• Wang, L., Bi, C., Cai, H., Liu, B., Zhong, X., Deng, X., & Wang, D. (2015). The therapeutic effect of chlorogenic acid against Staphylococcus aureus infection through sortase A inhibition. Frontiers in Microbiology, 6, 1031.
• Craft, K. M., Nguyen, J. M., Berg, L. J., & Townsend, S. D. (2019). Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. MedChemComm, 10(8), 1231-1241.
• Wang, Z., Cai, R., Wang, G., Guo, Z., Liu, X., Guan, Y., & Gu, J. (2021). Combination therapy of phage vB_KpnM_P-KP2 and gentamicin combats acute pneumonia caused by K47 serotype Klebsiella pneumoniae. Frontiers in microbiology, 12, 674068.
• de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J., de Sousa Cartágenes, M. D. S., Filho, A. K., do Nascimento, F. R., … & de Andrade Monteiro, C. (2018). Candida infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. Frontiers in microbiology, 9, 1351.
• Fleeman, R. M., Debevec, G., Antonen, K., Adams, J. L., Santos, R. G., Welmaker, G. S., & Shaw, L. N. (2018). Identification of a novel polyamine scaffold with potent efflux pump inhibition activity toward multi-drug resistant bacterial pathogens. Frontiers in microbiology, 9, 1301.
• Abdalla, M. A., & McGaw, L. J. (2018). Bioprospecting of South African plants as a unique resource for bioactive endophytic microbes. Frontiers in pharmacology, 9, 456.
• Atriwal, T., Azeem, K., Husain, F. M., Hussain, A., Khan, M. N., Alajmi, M. F., & Abid, M. (2021). Mechanistic understanding of Candida albicans biofilm formation and approaches for its inhibition. Frontiers in Microbiology, 12, 638609.